Post job

Axcan Pharma US Inc main competitors are Sanofi US, Takeda Pharmaceuticals U.S.A., Inc., and Daiichi Sankyo.

Competitor Summary. See how Axcan Pharma US Inc compares to its main competitors:

  • Sanofi US has the most employees (110,000).
  • Employees at Sanofi US earn more than most of the competitors, with an average yearly salary of $88,931.
Work at Axcan Pharma US Inc?
Share your experience

Axcan Pharma US Inc vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1991
4.2
Birmingham, AL1$470.4M525
Evoke Pharma
2007
3.7
Solana Beach, CA1$1.0M6
1998
4.7
Deerfield, IL14$12.1B30,481
1995
4.0
Newark, CA2$342.7M494
1985
4.3
Fairfield, NJ1$145.0M300
1901
4.3
Kalamazoo, MI1$130.0M350
1996
4.5
San Diego, CA1$218.0M290
-
3.9
Sanford, FL1$7.5M46
2000
4.3
Newport, KY1$18.8M100
2005
4.8
Parsippany-Troy Hills, NJ2$9.0B15,348
1995
4.8
Woodcliff Lake, NJ2$5.3B1,864
1991
4.5
Campbell, CA1$73.2M57
1919
4.7
Maple Grove, MN4$420.0M550
Odyssey Pharmaceuticals Inc
2000
3.7
East Hanover, NJ1$6.2M9
1897
4.0
Ferndale, MI1$66.5M200
1973
4.3
Bridgewater, NJ1$980.0M110,000
1997
4.7
Malvern, PA3$2.6B385
Schering-Plough Animal Health Corporation
-
3.8
----
1996
3.8
Morristown, NJ1$146.1M171
1878
4.4
Florham Park, NJ2$50.0M6,082
1980
4.9
Parsippany-Troy Hills, NJ2$2.4B6,500

Rate how well Axcan Pharma US Inc differentiates itself from its competitors.

Zippia waving zebra

Axcan Pharma US Inc salaries vs competitors

Among Axcan Pharma US Inc competitors, employees at Sanofi US earn the most with an average yearly salary of $88,931.

Compare Axcan Pharma US Inc salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Axcan Pharma US Inc
$71,660$34.45-
Evoke Pharma
$65,171$31.33-
Takeda Pharmaceuticals U.S.A., Inc.
$85,837$41.27-
Depomed
$72,486$34.85-
Brad Pharm
$65,801$31.64-
Pharmacia
$76,833$36.94-

Compare Axcan Pharma US Inc job title salaries vs competitors

CompanyHighest salaryHourly salary
Axcan Pharma US Inc
$89,975$43.26
Pernix Therapeutics Holdings
$98,945$47.57
Upsher-Smith Laboratories
$98,109$47.17
VIVUS
$95,351$45.84
Schering-Plough Animal Health Corporation
$90,029$43.28
Eisai
$87,198$41.92
Santarus
$84,555$40.65
Shionogi
$84,517$40.63
Hill Dermaceuticals
$84,155$40.46
Odyssey Pharmaceuticals Inc
$83,819$40.30
Ferring Pharmaceuticals
$83,580$40.18
Brad Pharm
$83,499$40.14
Ferndale Laboratories
$83,391$40.09
Xanodyne Pharmaceuticals
$83,363$40.08
Daiichi Sankyo
$82,912$39.86
Endo Pharmaceuticals Inc
$82,882$39.85
Depomed
$82,821$39.82
Takeda Pharmaceuticals U.S.A., Inc.
$82,769$39.79
Pharmacia
$82,549$39.69
Sanofi US
$82,251$39.54

Do you work at Axcan Pharma US Inc?

Does Axcan Pharma US Inc effectively differentiate itself from competitors?

Axcan Pharma US Inc jobs

Axcan Pharma US Inc demographics vs competitors

Compare gender at Axcan Pharma US Inc vs competitors

Job titleMaleFemale
Ferring Pharmaceuticals48%52%
Eisai50%50%
Daiichi Sankyo51%49%
Endo Pharmaceuticals Inc52%48%
VIVUS59%41%
Axcan Pharma US Inc--

Compare race at Axcan Pharma US Inc vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
59%17%10%11%3%
9.4
60%15%11%10%4%
9.5
58%13%12%13%4%
9.7
60%13%12%11%4%
9.8
62%13%12%10%4%
9.8
59%14%11%12%4%
9.9

Axcan Pharma US Inc and similar companies CEOs

CEOBio
Dan Peisert
Depomed

An intuitive leader who engenders a deep level of trust and loyalty while providing a clear vision and business strategy, with a proven track record in the pharmaceutical, generic, biotechnology and consumer product industries. Recognized for entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise, all driving shareholder value. Open to contract C-level and Board of Director positions.

John Amos
VIVUS

John has over 20 years of healthcare experience with 10 years directly in the cancer field. He is a board member or trusted advisor on active investments in Cancer, Dermatology, Diabetes, Anatomical Pathology, Generic Pharmaceuticals, Nuclear Pharmaceuticals, Health Payments and Health Information Technology through Bioveda China Fund, Amorperum Health and with a small number of top tier Private Equity Healthcare Firms. He is very active in board roles with a variety of healthcare companies in Israel, China, India and the US. Some of his past boards include Prodigy Health, which sold to Aetna (NYSE:AET) , and CITIC Pharmaceuticals, which sold to Shanghai Pharmaceuticals (SH:601607). Previously, John was the CEO of Oncology Therapeutics Network, which sold to McKesson, President of Oncology Services at Bristol Myers Squibb, and a Vice President at McKesson. He was a co- founder of Cancer Centers of Excellence and an early investor in Oncology Molecular Imaging. John studied economics and physics at University of California at Davis and has a Bachelor of Science from University of the State of New York. John served for 12 years in the United States Air Force and Air National Guard. He is currently a member of YPO and is active with the Wounded Warrior Project.

Ken Keller
Daiichi Sankyo

Haruo Naito
Eisai

Haruo Naito is a Board Member at Eisai. He has worked as Director at Eisai, President/CEO at Eisai, and Executive Vice President at Eisai. Haruo works or has worked as CHAIRMAN at The Naiito Foundation. He attended Keio University and Northwestern University.

Sudheendra Kulkarni
Ferring Pharmaceuticals

Country Manager enabling teams to deliver the present and charter the future aspirations, setting vision, strategising to capitalise on emerging opportunities in India and South Asian regions. P&L leader with multiple TA domain expertise, and across geographies in leading MNC,Indian companies with cultural diversity. Expertise in healthcare Sales& Marketing, Strategy, Business operations, new business venture management, strategic planning, managing acquisition, strategic alliance management, and International Business ( Includes Indian subcontinent of Srilanka, Bangladesh, Pakistan, Maldives etc), and exposure across AP markets. Expertise in leading profitable growth at South west Asia cluster country level. specialty,chronic and mass base business units across leading MNC & Indian companies.Setting up of Key Account Management and international business.

Gary D. Glick
Odyssey Pharmaceuticals Inc

Mark Morse
Pharmacia

Paul Hudson
Sanofi US

Axcan Pharma US Inc competitors FAQs

Search for jobs